Feb 14, 2025 • 7:30 am EST CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting ADC Demonstrates Encouraging Safety and Broader Efficacy in Phase 1 Study in the US and UK Presented at ASCO-GU 2025
Feb 11, 2025 • 7:30 am EST Corbus Pharmaceuticals Announces Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at 2025 ASCO-GU
Jan 28, 2025 • 8:00 am EST Corbus Pharmaceuticals to Present at the Guggenheim SMID Cap Biotech Conference
Jan 8, 2025 • 8:00 am EST Corbus Pharmaceuticals Announces that Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at ASCO GU 2025
Jan 6, 2025 • 8:00 am EST Corbus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Dec 9, 2024 • 7:00 am EST Corbus Pharmaceuticals Announces Dosing of First Patient in its First-In-Human Study of CRB-601 to Treat Patients with Advanced Solid Tumors
Dec 3, 2024 • 7:00 am EST FDA Grants Fast Track Designation to CRB-701 for the Treatment of Relapsed or Refractory Metastatic Cervical Cancer
Nov 21, 2024 • 8:00 am EST Corbus Pharmaceuticals to Present at the 7th Annual Evercore HealthCONx Conference
Nov 12, 2024 • 8:00 am EST Corbus Pharmaceuticals to Present at the Jefferies London Healthcare Conference
Nov 7, 2024 • 7:00 am EST Corbus Pharmaceuticals Reports 3rd Quarter 2024 Financial Results and Provides a Corporate Update